S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
Log in

OHR Pharmaceutical Stock Price, News & Analysis (NASDAQ:OHRP)

Today's Range N/A
50-Day Range
$3.99
MA: $5.01
$5.88
52-Week Range N/A
Volume28,100 shs
Average Volume240,406 shs
Market Capitalization$13.84 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84
OHR Pharmaceutical, Inc operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OHRP
CUSIPN/A
Phone212-682-8452

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.86 per share

Profitability

Net Income$-13,230,000.00

Miscellaneous

Employees3
Market Cap$13.84 million
Next Earnings Date1/1/2020 (Estimated)
OptionableOptionable

Receive OHRP News and Ratings via Email

Sign-up to receive the latest news and ratings for OHRP and its competitors with MarketBeat's FREE daily newsletter.


OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions

What is OHR Pharmaceutical's stock symbol?

OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."

When did OHR Pharmaceutical's stock split? How did OHR Pharmaceutical's stock split work?

Shares of OHR Pharmaceutical reverse split on the morning of Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 1st 2019. An investor that had 100 shares of OHR Pharmaceutical stock prior to the reverse split would have 5 shares after the split.

How were OHR Pharmaceutical's earnings last quarter?

OHR Pharmaceutical Inc (NASDAQ:OHRP) posted its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.20) EPS for the quarter. View OHR Pharmaceutical's Earnings History.

When is OHR Pharmaceutical's next earnings date?

OHR Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, January 1st 2020. View Earnings Estimates for OHR Pharmaceutical.

Has OHR Pharmaceutical been receiving favorable news coverage?

Media stories about OHRP stock have trended somewhat negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OHR Pharmaceutical earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for OHR Pharmaceutical.

Who are some of OHR Pharmaceutical's key competitors?

What other stocks do shareholders of OHR Pharmaceutical own?

Who are OHR Pharmaceutical's key executives?

OHR Pharmaceutical's management team includes the folowing people:
  • Dr. Jason Scott Slakter, CEO, Pres & Director (Age 61)
  • Mr. Samuel Backenroth, CFO, VP of Bus. Devel. & Sec. (Age 35)
  • Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 55)
  • Dr. Marlene Modi, Head of Preclinical & Regulatory Affairs

How do I buy shares of OHR Pharmaceutical?

Shares of OHRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

How big of a company is OHR Pharmaceutical?

OHR Pharmaceutical has a market capitalization of $0.00. OHR Pharmaceutical employs 3 workers across the globe.View Additional Information About OHR Pharmaceutical.

What is OHR Pharmaceutical's official website?

The official website for OHR Pharmaceutical is http://www.ohrpharmaceutical.com/.

How can I contact OHR Pharmaceutical?

OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected]


MarketBeat Community Rating for OHR Pharmaceutical (NASDAQ OHRP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  465
MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote "Outperform" if you believe OHRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OHRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel